Camlipixant Discontinued...

Research evidence excerpt

Camlipixant Discontinued...

Update

July 17, 2026 09:37 AM GMT

Morgan Stanley & Co. International plc+MGSK plc | Europe Sarita Kapila

Equity Analyst

Camlipixant Discontinued... Sarita.Kapila@morganstanley.comThibault Boutherin +44 20 7425-1320

Thibault.Boutherin@morganstanley.com +44 20 7425-9688

Key Takeaways Adithya Venkat

Research Associate

GSK reported topline results from the Phase 3 CALM-1 and CALM-2 trials Adithya.Venkat@morganstanley.com +44 20 7425-2216

evaluating camlipixant in refractory chronic cough.

GSK plc (GSK.L, GSK LN)

CALM-1 met the primary endpoint with camlipixant 50mg BID, reducing 24-hour ADRGSK.N

Pharmaceuticals | United Kingdom

cough frequency vs placebo at Week 12, while CALM-2 did not.

Stock Rating Underweight

Camlipixant 25mg BID also failed to reach statistical significance in either study. Industry View In-Line

Price target 1,750p

Consensus currently factors ~£750m risk adj camlipixant peak sales, (~£1.3bn Shr price, close (Jul 16, 2026) 1,956p

52-Week Range 2,282-1,315p

peak risk unadj), removing these would present a ~4% cut to outer-year earnings Mkt cap, curr (mn) £79,773

Camlipixant discontinued following CALM-1 & CALM-2 results; 4% cut to

consensus outer year earnings. GSK reported topline Phase 3 results for

camlipixant in refractory chronic cough, with CALM-1 meeting its primary endpoint

as 50mg BID demonstrated a statically significant reduction in 24-hour cough

frequency versus placebo at Week 12, while CALM-2 failed to reach statistical

significance on the same endpoint at Week 24. The 25mg BID dose was not

statistically significant in either study, and no headline efficacy figures were

disclosed. Based on the aggregate data, GSK has decided to discontinue further

development of camlipixant in RCC, which we view as a negative